<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512380</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-069</org_study_id>
    <nct_id>NCT02512380</nct_id>
  </id_info>
  <brief_title>Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer</brief_title>
  <official_title>Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      gastric cancer is a highly aggressive malignancy with a poor overall outcome. The purpose of
      this study is to evaluate the 5-year survival of neoadjuvant S1, oxaliplatin, and docetaxel
      (SLOT) versus S1, oxaliplatin(SOX) in patients with locally advanced, resectable
      gastric/esophagogastric junction (EGJ) cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two arms, phase 3 study of neoadjuvant S1, oxaliplatin, and docetaxel (SLOT) versus S1,
      oxaliplatin(SOX) in patients with locally advanced, resectable gastric/esophagogastric
      junction (EGJ) cancer. 380 Patients will be enrolled in this trial. The primary objective of
      this study is to determine the 5-year survival of the two arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 year overall survival</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year relapse free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complete resection rate (R0)</measure>
    <time_frame>2.5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>2.5 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life questionnaire</measure>
    <time_frame>6 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>SLOT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOX group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel;oxaliplatin;s1</intervention_name>
    <description>Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .</description>
    <arm_group_label>SLOT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin;s1</intervention_name>
    <description>oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .</description>
    <arm_group_label>SOX group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven gastric or GE junction adenocarcinoma;

          -  Age: 18 to 70;

          -  ECOG 0-2;

          -  Adenocarcinoma of the stomach or GE junction according to staging classification TNM
             Scannographic: T3-4 N0/N + M0 ;

          -  Completion of baseline quality of life questionnaire

          -  Adequate bone marrow functions (ANC ≥ 1,500/ul, blood platelet ≥ 100,000/ul,
             haemoglobin ≥ 10g/dl);

          -  Adequate renal functions(serum creatinine ≤ 1.5mg/dl)

          -  liver functions (serum bilirubin ≤ 1.5UNL, AST/ALT ≤ 3 times(normal value)

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy;

          -  Active infection requiring antibiotics

          -  Pregnant, lactating women

          -  Psychiatric illness, epileptic disorders

          -  Concurrent systemic illness not appropriate for chemotherapy

          -  History of other malignancy within 5 years except for non-melanoma skin cancer, cervix
             in situ carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Huang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Hospital, CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Huang, M.D.</last_name>
    <phone>8610-87788103</phone>
    <email>huangjingwg@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Huang, M.D</last_name>
    <phone>8610-87788103</phone>
    <email>huangjingwg@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Wang, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Huang</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

